SCHEMBL7191977

SCHEMBL7191977

CCOC(=O)c1cc(I)ccc1OCCC(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ TSHR P16473 2/20 0.41
▸ MAP2K2 P36507 1/20 0.40
▸ MAP2K1 Q02750 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ GABRA1 P14867 2/20 0.39
▸ GABRA3 P34903 2/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA2 P47869 1/20 0.39
▸ GABRA4 P48169 1/20 0.39
▸ GABRA6 Q16445 1/20 0.39
▸ CA12 O43570 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA7 P43166 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30754659 0.86 TSHR (0.45) TSHRMAP2K2MAP2K1GABRA1GABRA3
SCHEMBL24962709 0.86 TSHR (0.45) TSHRMAP2K2MAP2K1GABRA1GABRA3
SCHEMBL12942076 0.84 TSHR (0.49) HTTSMN1; SMN2TSHRMAP2K2MAP2K1
SCHEMBL7190979 0.83 HTT (0.51) HTTKDM4EALDH1A1XDHMAPK1
SCHEMBL7185662 0.83 HTT (0.46) HTTKDM4EMAP2K1ESR1GABRA1
SCHEMBL23882961 0.81 FDPS (0.41) KDM4ESMN1; SMN2TSHRMAP2K2MAP2K1
SCHEMBL4627163 0.79 TSHR (0.44) TP53TSHRMAP2K2MAP2K1ESR1
SCHEMBL6467757 0.79 LMNA (0.50) HTTSMN1; SMN2TSHRMAP2K2MAP2K1
SCHEMBL26159113 0.79 FDPS (0.39) KDM4ESMN1; SMN2TSHRMAP2K2MAP2K1
SCHEMBL14974855 0.78 HTT (0.46) HTTKDM4ESMN1; SMN2TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 — — EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 — — US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 — — US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO HTT 1549/4885KDM4E 2275/4885SMN1; SMN2 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback